Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With... Circulation RESEARCH LETTER Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis Nana Pogosova, MD; Jacqueline Bosch , PhD; Deepak L. Bhatt , MD; Keith A.A. Fox , MBChB; Stuart J. Connolly , MD; Marco Alings, MD; Peter Verhamme , MD; Eva Muehlhofer , MD; Olga Shestakovska , MSc; Salim Yusuf , MBBS; John W. Eikelboom , MBBS he COMPASS trial (Cardiovascular Outcomes for versus 28.3 kg/m , P=0.01), had lower blood pressure People using Anticoagulation Strategies) demon- (133/75 versus 136/78, P =0.01), were for diastolic blood pressure Tstrated that, in patients with chronic coronary artery more likely to be a current or former smoker (78.4% ver- disease and peripheral artery disease (PAD), the com- sus 68.0%, P=0.02), and were more likely to be taking bination of rivaroxaban 2.5 mg twice daily and aspirin a diuretic (39.2% versus 29.7%, P=0.04). The combina- 100 mg once daily compared with aspirin 100 mg once tion of rivaroxaban 2.5 mg twice daily and aspirin 100 daily reduced cardiovascular death, stroke, or myocardial mg once daily compared with aspirin 100 mg once daily infarction by 24% and mortality by 18%, and increased reduced the risk of VTE http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/rivaroxaban-2-5-mg-twice-daily-plus-aspirin-reduces-venous-0aXc0247DC

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
© 2022 American Heart Association, Inc.
ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/circulationaha.122.059405
Publisher site
See Article on Publisher Site

Abstract

Circulation RESEARCH LETTER Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis Nana Pogosova, MD; Jacqueline Bosch , PhD; Deepak L. Bhatt , MD; Keith A.A. Fox , MBChB; Stuart J. Connolly , MD; Marco Alings, MD; Peter Verhamme , MD; Eva Muehlhofer , MD; Olga Shestakovska , MSc; Salim Yusuf , MBBS; John W. Eikelboom , MBBS he COMPASS trial (Cardiovascular Outcomes for versus 28.3 kg/m , P=0.01), had lower blood pressure People using Anticoagulation Strategies) demon- (133/75 versus 136/78, P =0.01), were for diastolic blood pressure Tstrated that, in patients with chronic coronary artery more likely to be a current or former smoker (78.4% ver- disease and peripheral artery disease (PAD), the com- sus 68.0%, P=0.02), and were more likely to be taking bination of rivaroxaban 2.5 mg twice daily and aspirin a diuretic (39.2% versus 29.7%, P=0.04). The combina- 100 mg once daily compared with aspirin 100 mg once tion of rivaroxaban 2.5 mg twice daily and aspirin 100 daily reduced cardiovascular death, stroke, or myocardial mg once daily compared with aspirin 100 mg once daily infarction by 24% and mortality by 18%, and increased reduced the risk of VTE

Journal

Circulation – Wolters Kluwer Health

Published: Jun 21, 2022

References

  • Rivaroxaban with or without aspirin in stable cardiovascular disease.
    Eikelboom, JW; Connolly, SJ; Bosch, J; Dagenais, GR; Hart, RG; Shestakovska, O; Diaz, R; Alings, M; Lonn, EM; Anand, SS
  • Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease.
    Eikelboom, JW; Bhatt, DL; Fox, KAA; Bosch, J; Connolly, SJ; Anand, SS; Avezum, A; Berkowitz, SD; Branch, KRH; Dagenais, GR
  • Rivaroxaban in peripheral artery disease after revascularization.
    Bonaca, MP; Bauersachs, RM; Anand, SS; Debus, ES; Nehler, MR; Patel, MR; Fanelli, F; Capell, WH; Diao, L; Jaeger, N
  • Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries.
    Siegal, DM; Eikelboom, JW; Lee, SF; Rangarajan, S; Bosch, J; Zhu, J; Yusuf, S
  • Perioperative aspirin for prevention of venous thromboembolism: the Perioperative Ischemia Evaluation-2 Trial and a pooled analysis of the randomized trials.
    Eikelboom, JW; Kearon, C; Guyatt, G; Sessler, DI; Yusuf, S; Cook, D; Douketis, J; Patel, A; Kurz, A; Allard, R